Karuna Therapeutics, a Boston-based biotech startup, said Monday it has raised $68 million in venture capital to advance clinical development of a radically different drug for schizophrenia.
The sum is on top of $42 million that Karuna, a privately held 10-year-old firm, raised last year for development of the experimental medicine, which company officials hope might cause fewer side effects than the schizophrenia drugs on the market.
